The direct cost and incidence of systemic fungal infections.
暂无分享,去创建一个
J. Beney | C. Reyes | L. Wilson | Johnny Beney | Leslie S Wilson | Carolina M Reyes | Michelle Stolpman | Julie Speckman | Karoline Allen | M. Stolpman | J. Speckman | K. Allen
[1] W J Martone,et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. , 1991, The American journal of medicine.
[2] M. McKenzie,et al. Trends and sources of nosocomial fungaemia , 1994, Mycoses.
[3] D. Goff,et al. Cost Analysis of Candida Infection among Surgical Intensive Care Unit Patients , 1996 .
[4] M. Halpern,et al. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] H. Gallis,et al. Amphotericin B: 30 years of clinical experience. , 1990, Reviews of infectious diseases.
[6] H. Belzberg,et al. The pattern of fungal infections in critically ill surgical patients. , 1995, The American surgeon.
[7] G. Noskin,et al. Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients , 1999, Bone Marrow Transplantation.
[8] L. Nicolle,et al. Candidemia at selected Canadian sites: results from the Fungal Disease Registry, 1992-1994. Fungal Disease Registry of the Canadian Infectious Disease Society. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[9] M. Richardson,et al. Diagnosis and prevention of fungal infection in the immunocompromized patient. , 1998, Blood reviews.
[10] J. Andersson,et al. The incidence and diagnosis of invasive fungal infections in liver transplant recipients. , 1990, Transplantation proceedings.
[11] D. Rice,et al. The economic cost of illness revisited. , 1976, Social security bulletin.
[12] T. Walsh,et al. Evolving risk factors for invasive fungal infections--all neutropenic patients are not the same. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] A. Davidson,et al. Cost of care for patients with human immunodeficiency virus infection. Patterns of utilization and charges in a public health care system. , 1993, Archives of internal medicine.
[14] Rice Dp,et al. The economic cost of illness revisited. , 1976 .
[15] M. Klepser,et al. Therapy of Candida Infections: Susceptibility Testing, Resistance, and Therapeutic Options , 1998, The Annals of pharmacotherapy.
[16] A. Voss,et al. Epidemiology of nosocomial fungal infections: invasive aspergillosis and the environment. , 1999, Diagnostic microbiology and infectious disease.
[17] M. Klepser,et al. The changing face of nosocomial candidemia: epidemiology, resistance, and drug therapy. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[18] T. Hodgson,et al. Cost-of-illness methodology: a guide to current practices and procedures. , 1982, The Milbank Memorial Fund quarterly. Health and society.
[19] M. Nahata,et al. A comparative review of conventional and lipid formulations of amphotericin B , 1999, Journal of clinical pharmacy and therapeutics.
[20] C N Smart,et al. The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke: a comparative analysis. , 1980, American journal of public health.
[21] P. Francioli,et al. Nosocomial infections in Swiss university hospitals: a multi-centre survey and review of the published experience. Swiss-Noso Network. , 1999, Schweizerische medizinische Wochenschrift.
[22] J. Karlowsky,et al. Candidemia in a Canadian tertiary care hospital from 1976 to 1996. , 1997, Diagnostic microbiology and infectious disease.
[23] A. Schuchat,et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. , 1999, The Journal of infectious diseases.
[24] P. Ribaud. Fungal infections and the cancer patient , 1997 .
[25] R. Wenzel. Nosocomial candidemia: risk factors and attributable mortality. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] E. Anaissie,et al. Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] W. Jarvis. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] C. Kauffman,et al. Role of azoles in antifungal therapy. , 1996, Clinical Infectious Diseases.
[29] M. Owings,et al. 1996 summary: National Hospital Discharge Survey. , 1998, Advance data.
[30] J. Hay. Econometric issues in modeling the costs of AIDS. , 1989, Health policy.
[31] R. Gaynes,et al. The National Nosocomial Infections Surveillance System: plans for the 1990s and beyond. , 1991, The American journal of medicine.
[32] R. Pinner,et al. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] B. Althaus,et al. Antifungal Prophylaxis in Bone Marrow Transplant , 1995, The Annals of pharmacotherapy.
[34] D. Ward,et al. Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[35] National Nosocomial Infections Surveillance (NNIS) System report, data summary from October 1986-April 1998, issued June 1998. , 1998, American journal of infection control.
[36] V. Krčméry. Emerging fungal infections in cancer patients. , 1996, The Journal of hospital infection.
[37] T. Miller,et al. The Medical Costs of Gunshot Injuries in the United States , 2000 .
[38] B. Lebeau,et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[39] Reed Jacobson,et al. Microsoft Excel 97 : ステップバイステップ , 1997 .
[40] L. Mieles,et al. Amphotericin B lipid complex in the treatment of invasive fungal infections in liver transplant patients. , 1997, Transplantation proceedings.
[41] E. Graves,et al. Advance Data from Vital and Health Statistics of the Centers for Disease Control and Prevention/national Center for Health Statistics , 1994 .
[42] Graves Ej,et al. National Hospital Discharge Survey , 2004 .
[43] K. Levit,et al. Health spending in 1998: signals of change. The Health Accounts Team. , 2018, Health affairs.
[44] R. Gaynes,et al. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. , 1999, Critical care medicine.
[45] M. Pfaller,et al. Epidemiology and control of fungal infections. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[46] R. Hajjeh. Disseminated histoplasmosis in persons infected with human immunodeficiency virus. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[47] F J Hellinger,et al. The lifetime cost of treating a person with HIV. , 1993, JAMA.
[48] C. Beck-Sague,et al. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. , 1993, The Journal of infectious diseases.